Ann: Appendix 3G, page-9

George, Your analysis shows a lack of understanding/depth between all three entities. For one, I think its safe to assume that if WHA had been trading that it would have suffered worse than these two as both Nuchev and Bubs had positive momentum before Covid. As a prior poster alluded to, there was talk of an institutional/soph placement at 15c/share which I believe values WHA at almost half Nuchev. As the Shangdong deal related to SAMR for there obsoleted conventional formula I think its safe to say thats toast. I would certainly appreciate guidance from WHA on what they think/budgeting for chemist warehouse sales.